article Open AccessTop 1% cited
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Clinical Cancer Research · 2011 · Vol. 17(13) · pp. 4550–4557
Steven A. Rosenberg✉(National Cancer Institute)James Chih‐Hsin Yang(National Cancer Institute)Richard M. Sherry(National Cancer Institute)Udai S. Kammula(National Cancer Institute)Marybeth S. Hughes(National Cancer Institute)Giao Q. Phan(National Cancer Institute)Deborah E. Citrin(National Cancer Institute)Nicholas P. Restifo(National Cancer Institute)Paul F. Robbins(National Cancer Institute)John R. Wunderlich(National Cancer Institute)Kathleen E. Morton(National Cancer Institute)Carolyn M. Laurençot(National Cancer Institute)Seth M. Steinberg(National Cancer Institute)Donald E. White(National Cancer Institute)Mark E. Dudley(National Cancer Institute)
Abstract
Cell transfer therapy with autologous TILs can mediate durable complete responses in patients with metastatic melanoma and has similar efficacy irrespective of prior treatment. Clin Cancer Res; 17(13); 4550-7. ©2011 AACR.
CAR-T cell therapy researchImmunotherapy and Immune ResponsesVirus-based gene therapy researchMedicineMelanomaAdoptive cell transferRegimenImmunotherapyAldesleukinInternal medicineMetastatic melanomaOncologyCD8
MeSH terms
AdolescentAdultAgedCombined Modality TherapyFemaleHumansMaleMelanomaMiddle AgedSurvival AnalysisImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingTelomereTreatment OutcomeLymphocyte Count
Citations
2,095
FWCI
59.28
field-weighted impact
References
45
Percentile
100%
vs. same field & year
Citations per year
Cited by
IL-2: The First Effective Immunotherapy for Human Cancer
The Journal of Immunology · 2014 · 1,253 citations
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Clinical Cancer Research · 2014 · 781 citations
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Frontiers in Immunology · 2020 · 767 citations
The immune contexture in human tumours: impact on clinical outcome
Nature reviews. Cancer · 2012 · 4,857 citations
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The Lancet Oncology · 2016 · 1,657 citations
Delivery technologies for cancer immunotherapy
Nature Reviews Drug Discovery · 2019 · 2,556 citations
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Cells · 2020 · 449 citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Nature reviews. Immunology · 2020 · 4,024 citations
References
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
Blood · 1990 · 1,514 citations
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Journal of Clinical Oncology · 1999 · 2,025 citations
Cancer immunotherapy: moving beyond current vaccines
Nature Medicine · 2004 · 2,953 citations
Categorical Data Analysis
Technometrics · 1991 · 9,086 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Final Version of 2009 AJCC Melanoma Staging and Classification
Journal of Clinical Oncology · 2009 · 4,551 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.